These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21197688)

  • 21. Effect of selective heart rate reduction through sinus node I
    Sisakian H; Sargsyan T; Khachatryan A
    Acta Cardiol; 2016 Jun; 71(3):317-22. PubMed ID: 27594127
    [No Abstract]   [Full Text] [Related]  

  • 22. [From results of BEAUTIFUL trial to results of SHIFT trial: BEAUTIFUL possibility to make a SHIFT in current guidelines].
    Lopatin IuM
    Kardiologiia; 2011; 51(5):85-90. PubMed ID: 21649600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Use and Indication of Ivabradine in Heart Failure.
    Dodd K; Lampert BC
    Heart Fail Clin; 2018 Oct; 14(4):493-500. PubMed ID: 30266358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The biological effects of ivabradine in cardiovascular disease.
    Speranza L; Franceschelli S; Riccioni G
    Molecules; 2012 Apr; 17(5):4924-35. PubMed ID: 22547315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT.
    Voors AA; van Veldhuisen DJ; Robertson M; Ford I; Borer JS; Böhm M; Komajda M; Swedberg K; Tavazzi L;
    Eur J Heart Fail; 2014 Apr; 16(4):426-34. PubMed ID: 24504937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation.
    Cappato R; Castelvecchio S; Ricci C; Bianco E; Vitali-Serdoz L; Gnecchi-Ruscone T; Pittalis M; De Ambroggi L; Baruscotti M; Gaeta M; Furlanello F; Di Francesco D; Lupo PP
    J Am Coll Cardiol; 2012 Oct; 60(15):1323-9. PubMed ID: 22981555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis.
    Busseuil D; Shi Y; Mecteau M; Brand G; Gillis MA; Thorin E; Asselin C; Roméo P; Leung TK; Latour JG; Des Rosiers C; Bouly M; Rhéaume E; Tardif JC
    Cardiology; 2010; 117(3):234-42. PubMed ID: 21212673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure.
    Komajda M; Böhm M; Borer J; Ford I; Krum H; Tase A; Tavazzi L; Swedberg K
    Eur J Heart Fail; 2013 Jan; 15(1):79-84. PubMed ID: 22892123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of selective I f-channel inhibition with ivabradine on hemodynamics in a patient with restrictive cardiomyopathy.
    Wenzel P; Abegunewardene N; Münzel T
    Clin Res Cardiol; 2009 Oct; 98(10):681-4. PubMed ID: 19711110
    [No Abstract]   [Full Text] [Related]  

  • 30. Selective pharmacological inhibition of the pacemaker channel isoforms (HCN1-4) as new possible therapeutical targets.
    Koncz I; Szél T; Jaeger K; Baczkó I; Cerbai E; Romanelli MN; Gy Papp J; Varró A
    Curr Med Chem; 2011; 18(24):3662-74. PubMed ID: 21774761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of the Funny Current Inhibitor Ivabradine in Cardiac Pharmacotherapy: A Systematic Review.
    Petite SE; Bishop BM; Mauro VF
    Am J Ther; 2018; 25(2):e247-e266. PubMed ID: 26910057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ivabradine: a selective If current inhibitor in the treatment of stable angina.
    Andrikopoulos G; Dasopoulou C; Sakellariou D; Tzeis S; Koulouris S; Kranidis A; Kappos K; Manolis AS
    Recent Pat Cardiovasc Drug Discov; 2006 Nov; 1(3):277-82. PubMed ID: 18221092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rate control with ivabradine: angina pectoris and beyond.
    Parakh N; Bhargava B
    Am J Cardiovasc Drugs; 2011; 11(1):1-12. PubMed ID: 21090826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial).
    Böhm M; Robertson M; Ford I; Borer JS; Komajda M; Kindermann I; Maack C; Lainscak M; Swedberg K; Tavazzi L
    Am J Cardiol; 2015 Dec; 116(12):1890-7. PubMed ID: 26508709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. I(f) inhibition in cardiovascular diseases.
    Thollon C; Vilaine JP
    Adv Pharmacol; 2010; 59():53-92. PubMed ID: 20933199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ivabradine: pharmacodynamic aspects of its clinical use.
    Stieber J
    Methods Find Exp Clin Pharmacol; 2008 Oct; 30(8):633-41. PubMed ID: 19088948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ivabradine: Heart Failure and Beyond.
    Chaudhary R; Garg J; Krishnamoorthy P; Shah N; Lanier G; Martinez MW; Freudenberger R
    J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):335-43. PubMed ID: 26721645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Ivabradine on Endothelial Function in Patients with Stable Angina Pectoris: Assessment with the Endo-PAT 2000 Device.
    Jedlickova L; Merkovska L; Jackova L; Janicko M; Fedacko J; Novakova B; Chmelarova A; Majernik J; Pella D
    Adv Ther; 2015 Oct; 32(10):962-70. PubMed ID: 26525390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does ivabradine exhibit a role in the reduction of bladder overactivity?
    Stamatiou K; Heretis I; Skoumbourdis E
    Int Urol Nephrol; 2008; 40(2):333-4. PubMed ID: 18240005
    [No Abstract]   [Full Text] [Related]  

  • 40. Emerging role of ivabradine for rate control in atrial fibrillation.
    Turley SL; Francis KE; Lowe DK; Cahoon WD
    Ther Adv Cardiovasc Dis; 2016 Dec; 10(6):348-352. PubMed ID: 27659287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.